Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically targeted agents raise new challenges to conventional drug development paradigms by highlight...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohrt, Holbrook E., Tumeh, Paul C., Benson, Don, Bhardwaj, Nina, Brody, Joshua, Formenti, Silvia, Fox, Bernard A., Galon, Jerome, June, Carl H., Kalos, Michael, Kirsch, Ilan, Kleen, Thomas, Kroemer, Guido, Lanier, Lewis, Levy, Ron, Lyerly, H. Kim, Maecker, Holden, Marabelle, Aurelien, Melenhorst, Jos, Miller, Jeffrey, Melero, Ignacio, Odunsi, Kunle, Palucka, Karolina, Peoples, George, Ribas, Antoni, Robins, Harlan, Robinson, William, Serafini, Tito, Sondel, Paul, Vivier, Eric, Weber, Jeff, Wolchok, Jedd, Zitvogel, Laurence, Disis, Mary L., Cheever, Martin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791805/
https://www.ncbi.nlm.nih.gov/pubmed/26981245
http://dx.doi.org/10.1186/s40425-016-0118-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791805/
https://www.ncbi.nlm.nih.gov/pubmed/26981245
http://dx.doi.org/10.1186/s40425-016-0118-0

Ejemplares similares